RBC Capital Starts Global Blood Therapeutics (GBT) at Outperform

RBC Capital analyst Gregory Renza initiates coverage on Global Blood Therapeutics (NASDAQ: GBT) with a Outperform rating and a price target of $75.00.

The analyst comments "We see Oxbryta as a first-in-class sickle hemoglobin (HbS) polymerization inhibitor with potential to become standard of care in sickle cell disease - enthusiasm from physicians and the company's persistent engagement efforts reinforce our confidence in seeing continued market uptake, capable of a COVID-19 recovery, with over $1.6B out-year global sales potential. We believe the value of GBT lies in the long-term potential of Oxbryta with upside opportunity from entrenchment, expansion efforts, and complementary pipeline assets."

For an analyst ratings summary and ratings history on Global Blood Therapeutics click here. For more ratings news on Global Blood Therapeutics click here.

Shares of Global Blood Therapeutics closed at $44.78 yesterday.

You May Also Be Interested In

• Noble Capital Starts Xerox (XRX) at Outperform
• Compass Point Upgrades Strawberry Fields REIT (STRW) to Buy
• Elastic NV. (ESTC) PT Raised to $90 at Stifel as Positive Bias Continues